Related Experiment Video

Updated: Jan 22, 2026

Author Spotlight: Workflow for Integrating POCUS Data into EHR for Managing Heart Failure Patients
03:47

Author Spotlight: Workflow for Integrating POCUS Data into EHR for Managing Heart Failure Patients

Published on: July 12, 2024

1.1K

The Influence of Cardiovascular Medications on Iron Metabolism in Patients with Heart Failure

Oana Sirbu1, Victorita Sorodoc2, Irina M Jaba3

  • 1Department of Internal Medicine, Gr. T. Popa University of Medicine and Pharmacy, 700115 Iasi, Romania.

Medicina (Kaunas, Lithuania)
|July 5, 2019
PubMed

Insights

Heart failure medications like beta blockers, ACE inhibitors, and calcium-channel blockers may affect iron metabolism. Close monitoring of iron deficiency is recommended for patients with heart failure on these drugs.

Area of Science:

  • Cardiology
  • Pharmacology
  • Hematology

Background:

  • Anemia in heart failure (HF) has complex causes, potentially involving drug therapies.
  • Understanding drug effects on iron metabolism in HF is crucial.

Purpose of the Study:

  • To assess the impact of beta blockers, ACE inhibitors, and calcium-channel blockers on iron metabolism in HF patients.
  • To investigate drug-induced iron deficiency in heart failure.

Main Methods:

  • Prospective observational study.
  • Included HF patients with iron deficiency (ferritin <100 μg/L or 100-300 μg/L with TSAT <20%).
  • Excluded anemia from other known causes.

Main Results:

  • Beta-blocker use correlated significantly with ferritin levels (p=0.02).
  • Calcium-channel blocker users had lower iron, hemoglobin, and hematocrit.
  • ACE inhibitor use showed an indirect correlation with hematocrit (p=0.04).

Conclusions:

  • This study adds evidence for drug-induced iron deficiency in heart failure.
  • Clinicians should monitor iron deficiency parameters in HF patients due to potential drug impacts.

Keywords:
angiotensin-converting enzyme inhibitorsbeta blockerscalcium-channel blockersheart failureiron deficiency

More Related Videos

Author Spotlight: Investigating HR-Dependent Cardiac Function in Mouse Models Through a Novel Atrial-Pacing Approach07:49

Author Spotlight: Investigating HR-Dependent Cardiac Function in Mouse Models Through a Novel Atrial-Pacing Approach

Published on: July 21, 2023

1.9K
Integration of Brain Tissue Saturation Monitoring in Cardiopulmonary Exercise Testing in Patients with Heart Failure04:20

Integration of Brain Tissue Saturation Monitoring in Cardiopulmonary Exercise Testing in Patients with Heart Failure

Published on: October 1, 2019

6.2K

Related Concept Videos

Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
227
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
790
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
3.0K
Heart Failure I: Introduction01:27

Heart Failure I: Introduction

Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
729
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
278
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
825